The appointment brings extensive expertise into the company, potentially boosting its advances in cancer immunotherapy.
FREMONT, CA: In the field of biotechnology, Bolt Biotherapeutics has established a robust presence with its efforts to harness the immune system for cancer treatment. The company recently announced the appointment of Randall Schatzman, Ph.D., as the CEO and a member of the Board of Directors.
Dr. Schatzman possesses over 30 years of biotech leadership experience, and until recently, served as the President and CEO of Alder BioPharmaceuticals. He successfully led the company from inception through robust registration-enabling programs, including positive Phase 3 trials and significant fundraisings.
His excellent track record makes him the best candidate to lead Bolt with his expert leadership, advancing the programs of the company and bolstering its immune-stimulating antibody conjugate (ISAC) technology. The ISAC represents a significant evolution in the field of cancer immunotherapies, with the potential to change the lives of cancer patients.
Dr. Schatzman will be joining the experienced cancer immunotherapy team, including the alumni of premier cancer therapeutics companies and Ed Engleman, M.D., the founder of Bolt, and the inventor of the technology which underlies the first FDA-approved immunotherapy. The Bolt team aims to prove the efficacy and safety of the novel technology and advance its deployment to the clinics. The preclinical data regarding the ISAC technology indicates the total eradication of hard to treat tumors and enablement of immunological memory for the prevention of tumor regeneration.
Alder was cofounded by Dr. Schatzman and his scientific team in 2004, and he led the company until 2018, guiding it through the discovery and patenting monoclonal antibody therapeutics, including eptinezumab, undergoing registration at the FDA for migraine prevention, and clazakizumab, currently being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure.
Prior to that, he served as the Senior Vice President of Discovery Research at Celltech R&D, where his team helped in the discovery of romosozumab. It was later licensed to Amgen in partnership. Before Celltech, he was at Syntex/Roche Bioscience, serving as a preclinical team leader for Cytovene, and team leader for Valcyte, which are now marketed drugs. He received his Ph.D. in Molecular Pharmacology from Emory University before the completion of an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. As an inventor, he has over 30 issued patents and has authored more than 40 peer-reviewed scientific publications.
Based in the San Francisco Bay Area, Bolt Biotherapeutics specializes in the development of Boltbody ISAC, a novel class of immuno-oncology therapeutics designed to eliminate tumors. It has exhibited its tumor terminating capabilities after the systemic administration in the preclinical studies. It led to the development of immunological memory, fueling durable clinical responses for patients.
The Boltbody platform leverages Biotherapeutics’ ISAC technology, harnessing the ability of TLR agonists to convert cold tumors into immunologically hot tumors, thus revealing the tumors to the immune system and allowing them to be invaded by tumor-killing cells. The platform has demonstrated its ability to terminate tumors by following a systemic administration in preclinical models. It has also led to the development of immunological memory, which can potentially translate into more durable clinical responses for patients.
The ISAC technology shows potential for a broad spectrum of antibodies, targeting tumor antigens expressed in all types of cancer. It is compatible with a varied category of patients, including the ones refractory to the current generation of checkpoint inhibitors. The team spearheading the technology has extensive expertise in oncology drug discovery and development. Bolt Biotherapeutics is backed by world-class investors, including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital, and Nan Fung Life Sciences.